Symbols / FOLD Stock $14.49 Amicus Therapeutics Inc

Healthcare • Biotechnology • United States • NGM
FOLD (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Bradley L. Campbell M.B.A.
Exch · Country NGM · United States
Market Cap 4.55B
Enterprise Value 4.70B
Income -27.11M
Sales 634.21M
FCF (ttm) 47.84M
Book/sh 0.88
Cash/sh 0.94
Employees 511
Insider 10d —
IPO May 31, 2007
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 17.69
PEG —
P/S 7.17
P/B 16.43
P/C —
EV/EBITDA 112.00
EV/Sales 7.41
Quick Ratio 1.72
Current Ratio 2.84
Debt/Eq 161.30
LT Debt/Eq —
EPS (ttm) -0.09
EPS next Y 0.96
EPS Growth -95.50%
Revenue Growth 23.70%
EPS Gr Q/Q -88.50%
Rev Gr Q/Q —
Earnings (next) 2026-05-04
Earnings (prior) 2026-05-04
ROA 2.48%
ROE -11.58%
ROIC —
Gross Margin 88.50%
Oper. Margin 8.61%
Profit Margin -4.28%
Shs Outstand 314.00M
Shs Float 311.44M
Insider Own 0.69%
Instit Own 104.39%
Short Float 7.03%
Short Ratio 6.36
Short Interest 21.92M
52W High 14.50
vs 52W High -0.07%
52W Low 5.51
vs 52W Low 162.98%
Beta 0.48
Impl. Vol. —
Rel Volume 1.35
Avg Volume 3.92M
Volume 5.29M
Target (mean) $14.50
Tgt Median $14.50
Tgt Low $14.50
Tgt High $14.50
# Analysts 5
Recom Hold
Prev Close $0.00
Price $14.49
Change —
About

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. As of April 27, 2026, Amicus Therapeutics, Inc. operates as a subsidiary of BioMarin Pharmaceutical Inc.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$14.50
Mean price target
2. Current target
$14.49
Latest analyst target
3. DCF / Fair value
$2.74
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$14.49
Low
$14.50
High
$14.50
Mean
$14.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-01-22 down Jefferies Buy → Hold $15
2025-12-29 down Leerink Partners Outperform → Market Perform $15
2025-12-22 down Citigroup Buy → Neutral $15
2025-12-19 down Needham Buy → Hold —
2025-12-19 down Cantor Fitzgerald Overweight → Neutral $15
2025-12-17 init Citigroup — → Buy $17
2025-11-06 main JP Morgan Overweight → Overweight $19
2025-11-05 main Goldman Sachs Neutral → Neutral $11
2025-09-18 up Needham Hold → Buy $14
2025-07-17 up Morgan Stanley Equal-Weight → Overweight $108
2025-05-02 main UBS Buy → Buy $22
2025-05-02 main Goldman Sachs Neutral → Neutral $9
2025-02-20 main Wells Fargo Overweight → Overweight $17
2025-02-20 reit Needham Hold → Hold —
2025-01-15 reit Cantor Fitzgerald Overweight → Overweight $21
2025-01-13 reit Needham Hold → Hold —
2024-12-13 down Morgan Stanley Overweight → Equal-Weight $12
2024-11-12 main JP Morgan Overweight → Overweight $17
2024-11-07 main Guggenheim Buy → Buy $15
2024-11-07 main UBS Buy → Buy $21
News
RSS: Latest FOLD news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-02 CAMPBELL BRADLEY LEWIS Chief Executive Officer — 22,500 $14.35 $322,839
2026-01-20 CAMPBELL BRADLEY LEWIS Chief Executive Officer — 75,000 $14.31 $1,073,182
2026-01-20 CAMPBELL BRADLEY LEWIS Chief Executive Officer — 75,000 $6.10 $457,500
2025-12-19 CLARK DAVID MICHAEL Officer — 25,642 $14.17 $363,380
2025-12-15 CAMPBELL BRADLEY LEWIS Chief Executive Officer — 77,926 $10.86 $846,011
2025-12-15 CAMPBELL BRADLEY LEWIS Chief Executive Officer — 70,426 $9.03 $635,947
2025-12-15 CLARK DAVID MICHAEL Officer — 25,643 $11.00 $282,073
2025-12-01 CAMPBELL BRADLEY LEWIS Chief Executive Officer — 14,587 $10.01 $146,011
2025-12-01 CAMPBELL BRADLEY LEWIS Chief Executive Officer — 14,587 $9.03 $131,721
2025-12-01 PROUT SAMANTHA WHITEMAN Officer — 32,193 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
634.21
+20.05%
528.29
+32.29%
399.36
+21.30%
329.23
Operating Revenue
634.21
+20.05%
528.29
+32.29%
399.36
+21.30%
329.23
Cost Of Revenue
72.93
+37.75%
52.94
+41.84%
37.33
-3.30%
38.60
Reconciled Cost Of Revenue
72.93
+37.75%
52.94
+41.84%
37.33
-3.30%
38.60
Gross Profit
561.28
+18.08%
475.35
+31.30%
362.03
+24.57%
290.63
Operating Expense
526.79
+19.38%
441.29
+1.32%
435.52
-12.03%
495.06
Research And Development
135.84
+24.21%
109.36
-28.23%
152.38
-44.92%
276.68
Selling General And Administration
383.49
+18.59%
323.38
+17.48%
275.27
+29.21%
213.04
Total Expenses
599.72
+21.34%
494.23
+4.52%
472.85
-11.39%
533.66
Operating Income
34.49
+1.25%
34.06
+146.35%
-73.49
+64.05%
-204.43
Total Operating Income As Reported
32.79
+31.81%
24.88
+132.22%
-77.21
+63.60%
-212.12
EBITDA
53.81
+83.10%
29.39
+131.92%
-92.08
+53.86%
-199.58
Normalized EBITDA
55.51
+43.90%
38.58
+151.83%
-74.43
+61.21%
-191.88
Reconciled Depreciation
7.46
-12.72%
8.55
+8.56%
7.87
+47.38%
5.34
EBIT
46.35
+122.39%
20.84
+120.85%
-99.95
+51.22%
-204.92
Total Unusual Items
-1.70
+81.48%
-9.19
+47.94%
-17.65
-129.40%
-7.69
Total Unusual Items Excluding Goodwill
-1.70
+81.48%
-9.19
+47.94%
-17.65
-129.40%
-7.69
Special Income Charges
-1.70
+81.48%
-9.19
+47.94%
-17.65
-129.40%
-7.69
Other Special Charges
—
—
13.93
—
Restructuring And Mergern Acquisition
0.00
-100.00%
9.19
+255.71%
2.58
+139.61%
1.08
Write Off
1.70
0.00
-100.00%
1.13
-82.86%
6.62
Net Income
-27.11
+51.68%
-56.11
+62.99%
-151.58
+35.92%
-236.57
Pretax Income
0.19
+100.66%
-28.76
+80.84%
-150.10
+37.98%
-242.04
Net Non Operating Interest Income Expense
-42.84
+3.05%
-44.19
-2.60%
-43.07
-26.33%
-34.09
Interest Expense Non Operating
46.16
-6.93%
49.60
-1.10%
50.15
+35.10%
37.12
Net Interest Income
-42.84
+3.05%
-44.19
-2.60%
-43.07
-26.33%
-34.09
Interest Expense
46.16
-6.93%
49.60
-1.10%
50.15
+35.10%
37.12
Interest Income Non Operating
3.32
-38.65%
5.41
-23.61%
7.08
+134.06%
3.02
Interest Income
3.32
-38.65%
5.41
-23.61%
7.08
+134.06%
3.02
Other Income Expense
8.54
+145.85%
-18.63
+44.45%
-33.54
-853.27%
-3.52
Other Non Operating Income Expenses
10.24
+208.51%
-9.44
+40.57%
-15.89
-480.41%
4.18
Tax Provision
27.30
-0.18%
27.35
+1744.23%
1.48
+127.11%
-5.47
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+950.00%
0.00
Tax Effect Of Unusual Items
-0.36
+81.48%
-1.93
+47.94%
-3.71
-2308.70%
-0.15
Net Income Including Noncontrolling Interests
-27.11
+51.68%
-56.11
+62.99%
-151.58
+35.92%
-236.57
Net Income From Continuing Operation Net Minority Interest
-27.11
+51.68%
-56.11
+62.99%
-151.58
+35.92%
-236.57
Net Income From Continuing And Discontinued Operation
-27.11
+51.68%
-56.11
+62.99%
-151.58
+35.92%
-236.57
Net Income Continuous Operations
-27.11
+51.68%
-56.11
+62.99%
-151.58
+35.92%
-236.57
Normalized Income
-25.77
+47.25%
-48.85
+64.51%
-137.64
+39.90%
-229.03
Net Income Common Stockholders
-27.11
+51.68%
-56.11
+62.99%
-151.58
+35.92%
-236.57
Diluted EPS
—
-0.18
+64.71%
-0.51
+37.80%
-0.82
Basic EPS
—
-0.18
+64.71%
-0.51
+37.80%
-0.82
Basic Average Shares
—
304.38
+3.12%
295.16
+2.11%
289.06
Diluted Average Shares
—
304.38
+3.12%
295.16
+2.11%
289.06
Diluted NI Availto Com Stockholders
-27.11
+51.68%
-56.11
+62.99%
-151.58
+35.92%
-236.57
Depreciation Amortization Depletion Income Statement
7.46
-12.72%
8.55
+8.56%
7.87
+47.38%
5.34
Depreciation And Amortization In Income Statement
7.46
-12.72%
8.55
+8.56%
7.87
+47.38%
5.34
Line Item Trend 2025-12-31 2023-12-31
Total Assets
949.87
+22.11%
777.88
Current Assets
676.17
+39.98%
483.06
Cash Cash Equivalents And Short Term Investments
293.54
+2.56%
286.20
Cash And Cash Equivalents
214.01
-13.35%
246.99
Other Short Term Investments
79.53
+102.84%
39.21
Receivables
115.31
+31.58%
87.63
Accounts Receivable
115.31
+31.58%
87.63
Inventory
228.82
+283.31%
59.70
Raw Materials
131.17
+333.91%
30.23
Work In Process
61.30
+171.29%
22.60
Finished Goods
36.34
+429.12%
6.87
Prepaid Assets
—
—
Other Current Assets
38.51
-22.25%
49.53
Total Non Current Assets
273.70
-7.16%
294.82
Net PPE
48.25
-16.79%
57.98
Accumulated Depreciation
-31.82
-25.14%
-25.43
Properties
0.00
0.00
Land And Improvements
—
—
Machinery Furniture Equipment
10.09
+11.70%
9.03
Construction In Progress
0.00
-100.00%
3.81
Other Properties
36.91
-13.22%
42.53
Leases
33.07
+17.96%
28.03
Goodwill And Other Intangible Assets
211.71
-3.01%
218.29
Goodwill
197.80
+0.00%
197.80
Other Intangible Assets
13.91
-32.09%
20.49
Other Non Current Assets
13.74
-25.95%
18.55
Total Liabilities Net Minority Interest
675.63
+9.38%
617.71
Current Liabilities
237.83
+41.83%
167.69
Payables And Accrued Expenses
179.73
+62.37%
110.69
Payables
57.44
+108.46%
27.55
Accounts Payable
28.63
+89.35%
15.12
Other Payable
—
—
Current Accrued Expenses
122.29
+47.10%
83.14
Pensionand Other Post Retirement Benefit Plans Current
37.68
-1.63%
38.30
Total Tax Payable
28.81
+131.70%
12.43
Current Debt And Capital Lease Obligation
8.74
+5.01%
8.32
Current Capital Lease Obligation
8.74
+5.01%
8.32
Other Current Liabilities
11.68
+12.60%
10.37
Total Non Current Liabilities Net Minority Interest
437.80
-2.71%
450.02
Long Term Debt And Capital Lease Obligation
433.62
-0.71%
436.74
Long Term Debt
392.66
+1.24%
387.86
Long Term Capital Lease Obligation
40.96
-16.19%
48.88
Tradeand Other Payables Non Current
—
—
Non Current Deferred Liabilities
—
—
Non Current Deferred Taxes Liabilities
—
—
Other Non Current Liabilities
4.18
-68.54%
13.28
Stockholders Equity
274.24
+71.21%
160.17
Common Stock Equity
274.24
+71.21%
160.17
Capital Stock
3.04
+4.08%
2.92
Common Stock
3.04
+4.08%
2.92
Share Issued
310.86
+5.88%
293.59
Ordinary Shares Number
310.85
+5.88%
293.59
Treasury Shares Number
0.01
0.00
Additional Paid In Capital
3,014.46
+6.29%
2,836.02
Retained Earnings
-2,767.29
-3.10%
-2,684.07
Gains Losses Not Affecting Retained Earnings
24.11
+360.01%
5.24
Treasury Stock
0.07
—
Total Equity Gross Minority Interest
274.24
+71.21%
160.17
Total Capitalization
666.90
+21.69%
548.03
Working Capital
438.35
+38.99%
315.37
Invested Capital
666.90
+21.69%
548.03
Total Debt
442.36
-0.61%
445.06
Net Debt
178.65
+26.82%
140.86
Capital Lease Obligations
49.70
-13.11%
57.20
Net Tangible Assets
62.53
+207.60%
-58.11
Tangible Book Value
62.53
+207.60%
-58.11
Foreign Currency Translation Adjustments
24.12
+344.28%
5.43
Interest Payable
—
11.66
Other Equity Interest
—
0.07
Unrealized Gain Loss
-0.01
+94.15%
-0.19
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
33.15
+197.80%
-33.89
+50.95%
-69.09
+58.52%
-166.57
Cash Flow From Continuing Operating Activities
33.15
+197.80%
-33.89
+50.95%
-69.09
+58.52%
-166.57
Net Income From Continuing Operations
-27.11
+51.68%
-56.11
+62.99%
-151.58
+35.92%
-236.57
Depreciation Amortization Depletion
7.46
-12.72%
8.55
+8.56%
7.87
+47.38%
5.34
Depreciation And Amortization
7.46
-12.72%
8.55
+8.56%
7.87
+47.38%
5.34
Other Non Cash Items
2.57
+13.62%
2.26
+114.01%
-16.15
-535.02%
3.71
Stock Based Compensation
87.41
+2.95%
84.91
-1.36%
86.08
+12.50%
76.51
Asset Impairment Charge
-1.14
-112.36%
9.21
+237.73%
2.73
-85.00%
18.18
Deferred Tax
0.00
0.00
+100.00%
-4.94
-54977.78%
0.01
Deferred Income Tax
0.00
0.00
+100.00%
-4.94
-54977.78%
0.01
Operating Gains Losses
3.59
-77.91%
16.23
-51.61%
33.55
+448.05%
6.12
Net Foreign Currency Exchange Gain Loss
3.59
-77.91%
16.23
-17.23%
19.61
+220.42%
6.12
Change In Working Capital
-39.63
+59.94%
-98.94
-271.37%
-26.64
+33.19%
-39.88
Change In Receivables
-5.86
+69.92%
-19.48
+3.10%
-20.11
-16.03%
-17.33
Changes In Account Receivables
-5.86
+69.92%
-19.48
+3.10%
-20.11
-16.03%
-17.33
Change In Inventory
-111.48
-51.36%
-73.65
-65.09%
-44.61
-735.00%
-5.34
Change In Prepaid Assets
-1.38
-109.90%
13.96
+273.17%
-8.06
-30.16%
-6.19
Change In Payables And Accrued Expense
82.78
+601.07%
-16.52
-133.58%
49.20
+871.44%
-6.38
Change In Payable
82.78
+601.07%
-16.52
-133.58%
49.20
+871.44%
-6.38
Change In Account Payable
82.78
+601.07%
-16.52
-133.58%
49.20
+871.44%
-6.38
Change In Other Working Capital
-3.69
-13.45%
-3.25
-6.35%
-3.05
+34.12%
-4.64
Investing Cash Flow
-46.43
-8191.43%
-0.56
-100.57%
98.06
+6.23%
92.32
Cash Flow From Continuing Investing Activities
-46.43
-8191.43%
-0.56
-100.57%
98.06
+6.23%
92.32
Capital Expenditure
-3.30
+7.23%
-3.55
+52.24%
-7.44
-97.56%
-3.77
Capital Expenditure Reported
-3.30
+7.23%
-3.55
+52.24%
-7.44
-97.56%
-3.77
Net Investment Purchase And Sale
-43.14
-1541.23%
2.99
-97.16%
105.50
+13.85%
92.67
Purchase Of Investment
-94.41
+17.76%
-114.79
-25.14%
-91.72
+62.29%
-243.25
Sale Of Investment
51.27
-56.47%
117.78
-40.28%
197.23
-41.29%
335.93
Net Other Investing Changes
—
—
—
3.41
Financing Cash Flow
0.61
-88.09%
5.12
-91.70%
61.68
+926.44%
-7.46
Cash Flow From Continuing Financing Activities
0.61
-88.09%
5.12
-91.70%
61.68
+926.44%
-7.46
Net Issuance Payments Of Debt
-0.27
-180.41%
-0.10
+99.54%
-20.96
-7305.65%
-0.28
Issuance Of Debt
0.00
0.00
-100.00%
387.36
0.00
Repayment Of Debt
-0.27
-180.41%
-0.10
+99.98%
-408.32
-144181.98%
-0.28
Long Term Debt Issuance
0.00
0.00
-100.00%
387.36
0.00
Long Term Debt Payments
-0.27
-180.41%
-0.10
+99.98%
-408.32
-144181.98%
-0.28
Net Long Term Debt Issuance
-0.27
-180.41%
-0.10
+99.54%
-20.96
-7305.65%
-0.28
Net Common Stock Issuance
0.00
-100.00%
19.57
-78.95%
92.94
0.00
Proceeds From Stock Option Exercised
19.20
+150.16%
7.68
-25.27%
10.27
+138.35%
4.31
Net Other Financing Charges
-18.32
+16.81%
-22.02
-7.06%
-20.57
-79.05%
-11.49
Changes In Cash
-12.68
+56.78%
-29.33
-132.36%
90.65
+210.92%
-81.72
Effect Of Exchange Rate Changes
13.28
+429.37%
-4.03
-163.86%
6.31
+143.18%
-14.62
Beginning Cash Position
216.72
-13.34%
250.08
+63.33%
153.12
-38.62%
249.46
End Cash Position
217.32
+0.28%
216.72
-13.34%
250.08
+63.33%
153.12
Free Cash Flow
29.85
+179.72%
-37.44
+51.07%
-76.53
+55.07%
-170.34
Interest Paid Supplemental Data
43.61
-26.04%
58.96
+63.37%
36.09
+5.04%
34.36
Income Tax Paid Supplemental Data
14.89
+81.32%
8.21
-3.65%
8.53
+697.47%
1.07
Common Stock Issuance
0.00
-100.00%
19.57
-78.95%
92.94
0.00
Issuance Of Capital Stock
0.00
-100.00%
19.57
-78.95%
92.94
0.00
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category